Objectives: KPC-producing Klebsiella pneumoniae are an emerging public health problem around the globe. We defined the combinatorial pharmacodynamics and ability to suppress resistance of two 'old' antibiotics, fosfomycin and colistin, in time-kill experiments and hollow-fibre infection models (HFIM).
Introduction
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) has been identified by ESCMID and IDSA as an increasingly prominent nosocomial pathogen that is a therapeutic challenge.
1,2 KPC-Kp is often extensively drug resistant, 3 which has forced clinicians to utilize alternative agents, such as the polymyxins. 4 Patients with bacteraemia due to KPC-Kp who are treated with polymyxin monotherapy demonstrate unacceptably high mortality rates of up to 50%. 5, 6 Furthermore, the emergence of polymyxin resistance has increasingly been reported with monotherapy that is associated with the dramatic proliferation of resistant subpopulations. 7, 8 Therefore, new strategies for polymyxin combinations with non-traditional antibiotics are needed to combat KPC-Kp. Fosfomycin is an antimicrobial agent with a unique mechanism of arresting cell wall synthesis by inhibiting the initial step of peptidoglycan chain formation. 9 It remains active in vitro against most KPC-Kp and thus represents a potential treatment option for these organisms. 10, 11 However, microbiological cure rates in patients treated with fosfomycin monotherapy have been low due to the development of fosfomycin resistance. 12, 13 Despite the shortcomings of fosfomycin monotherapy, there may be utility in pairing it with other agents against KPC-Kp. The use of fosfomycin with a concurrent polymyxin is a rational combination as both agents have separate mechanisms of action. Additionally, fosfomycin has demonstrated a renal protective effect when co-administered with aminoglycosides vancomycin. 15 Observational clinical studies suggest that combining fosfomycin with a polymyxin is a promising treatment strategy for multidrug-resistant K. pneumoniae, [16] [17] [18] while in vitro studies have found low rates of synergy 19 or even antagonism. 20 To date, there have been no studies evaluating resistance suppression over a prolonged duration using humanized concentrations of colistin and fosfomycin. In the present study, we defined the combinatorial pharmacodynamics of colistin and fosfomycin against KPC-Kp by comprehensively profiling the time course of bacterial killing and emergence of resistance in a hollow-fibre infection model (HFIM).
Methods
Two KPC-2-expressing K. pneumoniae clinical isolates were utilized in the study. One isolate was susceptible to colistin and fosfomycin (KPC 9A: MIC colistin 0.25 mg/L and MIC fosfomycin 8 mg/L) while the other isolate was resistant to colistin and susceptible to fosfomycin (KPC 5A: MIC colistin 64 mg/L and MIC fosfomycin 32 mg/L). CAMHB was used for colistin microdilution MIC testing and CAMHB supplemented with glucose-6-phosphate (G6P; Sigma-Aldrich; 25 mg/L) was used for time-kill and HFIM experiments. Fosfomycin MIC values were obtained by agar dilution on Mueller-Hinton agar supplemented with G6P. Per EUCAST, resistance to colistin and fosfomycin was defined as MICs greater than 2 and 32 mg/L, respectively. 21 Time-kill experiments were conducted as previously described. 22 Briefly, overnight cultures of both K. pneumoniae isolates were adjusted in turbidity using supplemented MHB to achieve a 10 6 cfu/mL starting inoculum, approximating a urinary tract infection, low-burden pneumonia or intra-abdominal infection. [23] [24] [25] On the day of each experiment, fresh fosfomycin stocks (Sigma-Aldrich) of 8, 16, 32, 64, 128, 256 and 512 mg/L (normal clinical serum range $150 to 500 mg/L) [26] [27] [28] and colistin stocks (Sigma-Aldrich) of 0.25, 1 and 4 mg/L 29 were prepared for investigation. Bacterial suspensions were exposed to antibiotics for 48 h in 20 mL reaction vessels that were incubated in a 37 C water bath with constant shaking. Samples were collected at 0, 1, 2, 4, 8, 24, 28, 32 and 48 h, serially diluted in saline and then plated onto Mueller-Hinton agar for viable counting. Synergy was defined as a !2 log 10 cfu/mL decrease during combination exposure compared with the most active single agent.
To further define the pharmacodynamics of combination treatment, KPC 9A was investigated in an HFIM as detailed previously. 30 The pharmacokinetics of colistin in patients with hospital-acquired pneumonia were simulated to replicate drug concentrations expected in critically ill patients, with a free maximum concentration (fC max ) of 0.46mg/L, a free AUC 0-12 (fAUC 0-12 ) of 3.8 mgÁh/L and a t 1/2 of 7 h. 31 The simulated colistin pharmacokinetics were obtained from the clinical pharmacokinetic study by Zhao et al. 31 that analysed 11 Chinese patients with the following baseline characteristics: mean age 54.9 years (range 38-71 years), mean weight 58.8 kg (range 45.0-72.5 kg) and mean creatinine clearance of 130 mL/min (range 68-212 mL/min). A novel front-loaded regimen of fosfomycin was simulated, consisting of 4 g every 8 h on day 1 followed by 2 g every 8 h on days 2-5. Each dose of fosfomycin was administered as a 30 min infusion to target an fC max of 150 mg/L, an fAUC 0-8 of 443 mgÁh/L and a t 1/2 of 2 h. 32 During combination experiments, colistin was supplemented to maintain a profile consistent with a t 1/2 of 7 h. 33 Using a 10 6 cfu/mL inoculum, samples were periodically withdrawn from the HFIM over 120 h and plated onto Mueller-Hinton agar for viable counting. To track subpopulations of K. pneumoniae with varying levels of colistin and fosfomycin resistance, daily samples were also plated onto agar imbued with either colistin (0.25, 1, 4 and 10 mg/L, colistin-containing arms only) or fosfomycin ! 25 mg/L G6P (8, 32 and 128 mg/L, fosfomycin-containing arms only) for population analysis profiles.
Studies for pharmacokinetic validation of fosfomycin and colistin dosing in the HFIM were individually conducted prior to beginning the hollow fibre experiment. The collected samples were immediately stored at #80 C until analysis. Fosfomycin concentrations in the HFIM were determined using a biological assay that utilized Staphylococcus aureus (ATCC 29213) as an indicator organism. Overnight cultures of ATCC 29213 were diluted in Difco Antibiotic Medium 5 agar that was supplemented with G6P (25 mg/L) to achieve 10 6 cfu/mL. Colistin concentrations were determined by an LC-MS/MS method as previously described. 34 The LC-MS/MS system consisted of a Waters Alliance 2690 HPLC system (Milford, MA, USA) and a TSQ Quantum triple-quadrupole mass spectrometer equipped with an electrospray ionization probe (Thermo Finnigan, San Jose, CA, USA). The colistin A/B calibration curve was linear with R 2 .0.99 and had good reproducibility (coefficient of variation 7.2%) and accuracy (relative error 6.51%). The limit of detection was 0.0241/0.0439 mg/L for colistin A/B, respectively.
Results
The pharmacodynamic activities of colistin, fosfomycin and their combination in time-kill experiments against KPC 9A are depicted in Figure 1 (a1-e1). Fosfomycin and colistin alone produced extensive initial killing ($2 to 5 log 10 cfu/mL) within 8 h followed by regrowth to near the growth control despite being considered susceptible, as indicated by the MICs. Remarkably, all combinations containing .8 mg/L fosfomycin achieved synergy by 24 h, which was maintained to 48 h. In combination with fosfomycin, increasing colistin concentrations .0.25 mg/L had no apparent additional effect on the killing of KPC 9A. The synergistic combinations caused undetectable KPC 9A counts by 24 h. These time-kill data suggested that the presence or absence of regrowth at 48 h could be predicted based on undetectable bacterial counts at 24 h; no regrowth was observed when bacterial counts were 0 at 24 h.
Against KPC 5A in time-kill experiments (Figure 1a2-e2) , colistin monotherapy did not cause a reduction in viable bacterial counts at any time point. Alone, fosfomycin at concentrations of ,128, 128 and .128 mg/L caused maximal bacterial reductions at 4 h of $1, 2 and 3 log 10 cfu/mL, respectively. Unlike KPC 9A, synergy between colistin and fosfomycin versus colistin-resistant KPC 5A was only achieved at the highest concentration of both drugs (4 mg/L colistin and 512 mg/L fosfomycin at 48 h). Exposure to colistin and fosfomycin alone resulted in near complete regrowth at 48 h that was delayed by combinations utilizing 512 mg/L fosfomycin, which prevented the regrowth from achieving growth control levels.
Colistin and fosfomycin concentrations that mimicked human pharmacokinetics were examined alone and in combination against KPC 9A over 120 h in the dynamic HFIM (Figure 2a ). There was acceptable agreement between the observed and targeted pharmacokinetic profiles for fosfomycin (R 2 " 0.963, slope " 1.153 and intercept " #6.659) and colistin (R 2 " 0.714, slope " 1.072 and intercept " 0.003). Colistin monotherapy rapidly achieved a maximal bacterial reduction at 1 h of #3.88 log 10 cfu/mL, which was immediately followed by emergence of resistance and regrowth by 24 h. Following exposure to colistin monotherapy, total population regrowth occurred simultaneously with the expansion of subpopulations capable of growing on plates imbued with 1, 4 or 10 mg/L colistin from 0% (t " 0 h) to .25% (t " 24 h) to .50% (t " 48 h) of the total population (Figure 2b2) . Fosfomycin monotherapy displayed a maximal bacterial reduction of 2.41 log 10 cfu/mL at 6 h. Similar to colistin monotherapy, regrowth of KPC 9A total populations to near growth control levels occurred by 24 h, likely a result of the rapid proliferation of fosfomycin-resistant subpopulations (Figure 2b3) . Strikingly, combination therapy of colistin and fosfomycin Zhao et al.
caused total bacterial counts of KPC 9A to be undetectable (6.15 log 10 cfu/mL reduction) by 6 h with no observable growth up to 120 h. Subpopulations capable of growing on colistin or fosfomycin plates of any concentration followed a similar trend and were completely suppressed to undetectable counts by 48 h (Figure 2b4 ).
Discussion
Clinicians face a difficult task when treating infections caused by KPCKp, given its high degree of antimicrobial resistance. Colistin and fosfomycin are among the select few antibiotics that maintain activity Colistin and fosfomycin against KPC-producing K. pneumoniae JAC against KPC-Kp. However, frequent treatment failure and development of resistance in the clinic are reported when patients receive either agent as monotherapy. 12, 35 With regard to combinations with polymyxins and fosfomycin, there is currently a paucity of studies. Souli et al. 19 determined that 5 mg/L colistin combined with 100 mg/L fosfomycin against KPC-Kp resulted in bactericidal activity against $65% of isolates. Interestingly, the combination demonstrated synergy against only $12% of KPC-Kp isolates, although it is uncertain whether the low rate of synergy was due to poor activity of the combination or, rather, marked killing by either colistin or fosfomycin alone. Michalopoulos et al. 18 identified favourable clinical and microbiological outcomes in six patients with carbapenem-resistant K. pneumoniae infections who were treated with the combination of colistin and intravenous fosfomycin. Taken together, these studies that have investigated colistin in combination with fosfomycin against KPC-Kp support our investigation, which is the first to our knowledge to assess human simulated colistin/fosfomycin regimens in the HFIM against this pathogen. In the present study, a number of important observations were made. First, the colistin/fosfomycin combinations against the double-susceptible KPC-Kp isolate demonstrated sustained bactericidal activity. Second, in contrast to the double-susceptible Zhao et al.
isolate, killing against the colistin-resistant KPC-Kp was almost entirely driven by fosfomycin, where the addition of colistin yielded minimal benefit. From a mechanistic perspective, the enhanced bacterial killing by the combination may be a result of colistin permeabilizing the bacterial outer membrane and allowing fosfomycin better penetration to the site of action. 36, 37 Such a mechanism may explain the reduced activity of the combination towards the colistin-resistant isolate.
To further exploit the rapid bactericidal activity demonstrated by the combination in time-kill experiments, a proof-of-concept fosfomycin 'front load' was administered in the HFIM. Dosing fosfomycin in such a manner helped to determine whether high initial fosfomycin concentrations in combination with colistin could drive viable counts to near undetectable counts for 120 h. The HFIM results showed excellent combinatorial activity of the colistin/fosfomycin combination through 120 h against the colistin-susceptible KPC-Kp isolate and support future explorations of novel fosfomycin dosing schemes in an attempt to maximize its pharmacokinetics/ pharmacodynamics. Although fosfomycin is generally well tolerated, using a front load may have a number of added clinical benefits. Reducing the AUC may reduce the rate of hypokalaemia, which is commonly due to increased urinary excretion of potassium during infusions of fosfomycin. 38 Additionally, fosfomycin disodium (intravenous formulation) contains a high amount of sodium per dose, which can be troublesome for patients with baseline hepatic or cardiovascular abnormalities. Higher initial doses of fosfomycin have also been suggested as a means to overcome the lower initial C max values seen in critically ill patients, given their increased volumes of distribution. 39 Together, minimizing exposure by front loading fosfomycin may reduce adverse events while maintaining drug efficacy without precipitating drug resistance.
One important consideration for the translation of these data is the variation in drug clearance for critically ill patients, with previously reported mean colistin and fosfomycin half-lives ranging from 7.4 to 14.4 [40] [41] [42] and from 2 to 3.9 h, [26] [27] [28] respectively. The colistin and fosfomycin simulated clearances in the hollow fibre infection model (colistin t 1/2 " 7 h and fosfomycin t 1/2 " 2 h) were based on pharmacokinetic studies of patients with mostly normal renal function, but may underestimate the antimicrobial exposure expected for patients with impaired renal clearance. Another potential limitation of the current investigation is that the colistin-resistant KPC-Kp was not studied in the HFIM due to the limited synergy observed between colistin and fosfomycin in the time-kill experiments against this isolate. Still, the robust pharmacodynamic activity and suppression of resistant subpopulations for the combination may be of clinical utility and warrant further investigation.
In conclusion, our study demonstrated that the combination of colistin and fosfomycin may represent an important treatment option for KPC-Kp that is susceptible to colistin. To our knowledge, this is the first study to comprehensively analyse an array of colistin and fosfomycin concentrations against KPC-2-producing K. pneumoniae. Animal investigations using colistin/fosfomycin combinations against KPC-Kp are necessary to better optimize the use of rational combinations for the clinic.
